Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Q2 FY27 Results: Net Loss of ₹2.7 Cr, Loss Narrows

Oxygenta Pharmaceutical's board approved unaudited results for the quarter and half year ended 30 September 2026, showing quarterly revenue of Rs 3,351.41 lakhs and a net loss of Rs 273.53 lakhs. The filing includes the full SEBI results statement, balance sheet, cash flow and limited review report.

Key figure

Net loss ₹2.7 Cr

Oxygenta Pharmaceutical Q1 FY27 Results: Net Loss of ₹2.1 Cr, Loss Narrows

Oxygenta Pharmaceutical Ltd reported revenue from operations of ₹37 Cr (+145.0% YoY) and a net loss of ₹2.1 Cr for Q1 FY27.

Key figure

Net loss ₹2.1 Cr

Oxygenta Pharmaceutical Q4 FY26 Results: Net Loss of ₹1.7 Cr, Loss Narrows

Oxygenta Pharmaceutical Ltd reported revenue from operations of ₹49.6 Cr (+0.2% YoY) and a net loss of ₹1.7 Cr for Q4 FY26.

Key figure

Net loss ₹1.7 Cr

Oxygenta Pharmaceutical Financial Results

Oxygenta Pharmaceutical Limited reported its audited financial results for the year ended March 31, 2026. The company also announced key board appointments and auditor changes.